The addition of the Qualicaps FS3 unit to the company’s manufacturing capabilities is expected to increase overall efficiency at the Phase 2 production scale.
The unit, which is equipped with an inert gas purge system and capsule lifting feature, will allow the handling of oxygen sensitive drug products.
The inert gas purge system minimizes process defects by sending warmed air, or inert gas, into the headspace of the capsule.
The FS3 liquid filling and banding system is configured to handle clear or colored banding and gelatin or HPMC capsules ranging in sizes from 4 to 00.
Pharmatek CEO and CSO Jeffrey Bibbs said: "More efficient production of larger scale batches helps us to better support our clients through their late-stage Phase 2B clinical studies."